BioCentury
ARTICLE | Company News

Sobi grabs emapalumab, anticipates 2018 approval

July 20, 2018 10:11 PM UTC

Swedish Orphan Biovitrum AB (SSE:SOBI) received exclusive, worldwide rights from Novimmune S.A. (Plan-les-Ouates, Switzerland) to hematology candidate emapalumab (NI-0501).

Novimmune will receive SEK450 million ($50.8 million) up front in cash, plus SEK3.6 billion ($406.5 million) in additional payments over eight years. Sobi will cover all development and commercialization costs for the human mAb against interferon (IFN) gamma beginning in September. The deal is expected to close this quarter...